KALA BIO Makes Strategic Move with $6 Million Investment
KALA BIO, Inc. (NASDAQ: KALA), a biopharmaceutical company committed to advancing innovative therapies for rare and severe eye diseases, has recently signed a substantial securities purchase agreement worth $6 million with private investor David E. Lazar. This agreement primarily involves the acquisition of non-voting convertible preferred stock, which represents a notable financial boost for the company.
Leadership Changes Following Investment
As part of this agreement, David E. Lazar has been named KALA's new Chief Executive Officer and Chairman of the Board. This change marks a pivotal moment for KALA, as the company aims to align its leadership with a vision focusing on practical future prospects. Todd Bazemore, the former CEO, will continue to contribute to the company's Board, ensuring continuity during this transitional phase.
Clinical Trial Updates for KPI-012
On September 29, KALA faced challenges when its CHASE Phase 2b clinical trial for KPI-012, aimed at treating persistent corneal epithelial defect (PCED), failed to meet its primary healing endpoint. As a result of this setback, KALA temporarily halted KPI-012's development to conserve resources and reevaluate strategic paths. However, with Lazar's investment, the company is poised to restart the evaluation and redevelopment of its therapeutic candidates, potentially exploring various applications for KPI-012.
Lazar's Vision for KALA's Future
Mr. Lazar expressed his enthusiasm about the investment, stating his commitment to enhancing the company's product development while actively searching for strategic growth opportunities. He believes that with the unwavering backing of KALA’s Board, they can add significant value for stockholders.
Expertise in Restructuring and Strategic Planning
According to Todd Bazemore, Lazar's considerable experience in capital restructuring and reverse mergers will play a crucial role in KALA's future. Both leaders are optimistic about assessing new business opportunities and the strategic alternatives that could revolutionize KALA’s operations and market position.
Details of the Securities Purchase Agreement
During the agreement's initial closing, KALA will issue non-voting convertible Series AA preferred shares for Lazar's first investment installment of $1.8 million. The completion of this investment and a subsequent closing depends on obtaining stockholder approval at an upcoming meeting expected in the early part of 2026. If approved, the second closing will involve issuing Series AAA preferred stock, accompanied by a further investment of $4.2 million.
About KALA BIO, Inc.
KALA BIO is at the forefront of biological research and therapy development focusing on severe and rare ocular diseases. Utilizing its proprietary MSC-S platform, KALA's lead product candidate, KPI-012, is instrumental in creating therapies that contain a rich array of biofactors beneficial for corneal healing. Notably, it has received prestigious Orphan Drug and Fast Track designations from the FDA, signifying its potential transformative impact in treating PCED.
Contact Information for KALA BIO
If you wish to reach out for more information, you can contact:
David Lazar
Chief Executive Officer and Chairman of the Board
david@activistinvestingllc.com
Frequently Asked Questions
What is the significance of the $6 million investment for KALA BIO?
The investment will help KALA BIO continue its research and development of therapies for rare eye disease treatments.
Who is David E. Lazar?
David E. Lazar is the newly appointed CEO and Chairman of KALA BIO, with experience in capital restructuring.
What challenges did KALA BIO face in its recent clinical trials?
KALA’s recent trial for KPI-012 did not meet its primary endpoint of healing, prompting a review of their approach.
What are the next steps for KALA after the investment?
KALA plans to restart the evaluation of its therapeutic candidates and explore a variety of strategic opportunities.
How will stockholder approval impact the investment agreement?
Stockholder approval is necessary for concluding the agreement, allowing KALA to proceed with further investments.
